靶向PRMT1介导的FLT3甲基化破坏MLL重排急性淋巴细胞白血病维持
MLL重排急性淋巴细胞白血病(MLL-r ALL)复发源于耐药克隆持续存在,PRMT1在MLL-r ALL细胞中升高,抑制PRMT1可抑制白血病细胞生长和存活。PRMT1甲基化FLT3的R972/973位点,其致癌功能依赖FLT3甲基化。I型PRMT抑制剂MS023抑制白血病细胞活力与基线FLT3 R972/973甲基化水平平行,联合PKC412在患者来源小鼠异种移植中增强清除MLL-r ALL细胞。
要点
- PRMT1在MLL-r ALL细胞中升高,抑制PRMT1可抑制白血病细胞生长和存活。
- PRMT1甲基化FLT3 R972/973,其致癌功能依赖FLT3甲基化。
- MS023抑制白血病细胞活力与基线FLT3 R972/973甲基化水平平行。
核心结论
- 通过抑制PRMT1消除FLT3精氨酸甲基化是靶向MLL-r ALL细胞的有前景策略。
研究设计与样本
- 研究使用MLL-r ALL细胞、生化与计算分析、患者来源小鼠异种移植模型。
主要发现
- PRMT1在MLL-r ALL细胞中水平升高,抑制PRMT1显著抑制白血病细胞生长和存活。
- PRMT1甲基化FLT3的R972/973位点,其致癌功能依赖FLT3甲基化。
- 表达R972/973甲基化缺陷FLT3的细胞比表达Y969磷酸化缺陷FLT3的细胞表现出更强烈的凋亡和生长抑制。
- MS023抑制白血病细胞活力的能力与基线FLT3 R972/973甲基化水平平行。
- 在患者来源小鼠异种移植中,PKC412联合MS023比单用PKC412增强清除MLL-r ALL细胞。
临床怎么用
- 抑制PRMT1以消除FLT3精氨酸甲基化可能成为靶向MLL-r ALL细胞的策略。
- FLT3酪氨酸激酶抑制剂PKC412联合I型PRMT抑制剂MS023可能增强清除MLL-r ALL细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse remains the main cause of MLL-rearranged (MLL-r) acute lymphoblastic leukemia (ALL) treatment failure resulting from persistence of drug-resistant clones after conventional chemotherapy treatment or targeted therapy. Thus, defining mechanisms underlying MLL-r ALL maintenance is critical for developing effective therapy. PRMT1, which deposits an asymmetric dimethylarginine mark on histone/non-histone proteins, is reportedly overexpressed in various cancers. Here, we demonstrate elevated PRMT1 levels in MLL-r ALL cells and show that inhibition of PRMT1 significantly suppresses leukemic cell growth and survival. Mechanistically, we reveal that PRMT1 methylates Fms-like receptor tyrosine kinase 3 (FLT3) at arginine (R) residues 972 and 973 (R972/973), and its oncogenic function in MLL-r ALL cells is FLT3 methylation dependent. Both biochemistry and computational analysis demonstrate that R972/973 methylation could facilitate recruitment of adaptor proteins to FLT3 in a phospho-tyrosine (Y) residue 969 (Y969) dependent or independent manner. Cells expressing R972/973 methylation-deficient FLT3 exhibited more robust apoptosis and growth inhibition than did Y969 phosphorylation-deficient FLT3-transduced cells. We also show that the capacity of the type I PRMT inhibitor MS023 to inhibit leukemia cell viability parallels baseline FLT3 R972/973 methylation levels. Finally, combining FLT3 tyrosine kinase inhibitor PKC412 with MS023 treatment enhanced elimination of MLL-r ALL cells relative to PKC412 treatment alone in patient-derived mouse xenografts. These results indicate that abolishing FLT3 arginine methylation through PRMT1 inhibition represents a promising strategy to target MLL-r ALL cells.
引用
- Zhu Y, He X, Lin YC, et al. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. Blood. 2019. PMID: 31395602. doi:10.1182/blood.2019002457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。